一体式分支开窗支架移植物治疗腹主动脉瘤的早期机构经验
本回顾性单中心分析纳入2019年3月至2021年4月连续接受一体式分支开窗支架(Bif-FEVAR)治疗腹主动脉瘤的10例患者(100%男性,中位年龄78岁),术前中位最大瘤径68 mm[51-84],8例为腔内修复术后近端I型内漏。技术成功率100%,无患者发生术后重大不良事件,中位随访8个月[6-13]。作者认为Bif-FEVAR在目标动脉最低处与主动脉分叉间距离较短时技术可行,短期结果良好。
要点
- 10例患者(100%男性,中位年龄78岁)接受Bif-FEVAR,技术成功率100%。
- 8例因腔内修复术后近端I型内漏接受治疗,无患者发生术后重大不良事件。
- 作者认为在目标动脉最低处与主动脉分叉间距离较短时Bif-FEVAR技术可行,短期结果良好。
核心结论
- 作者认为,当目标动脉最低处与主动脉分叉之间距离较短时,Bif-FEVAR技术可行,短期结果良好。
- 作者指出,一体式分支开窗支架移植物将FEVAR的适应证扩展至目标肾动脉最低处与主动脉-髂动脉分叉间距离异常短的患者,或用于处理既有的分支型肾下支架移植物的分流。
研究设计与样本
- 回顾性单中心分析,纳入2019年3月至2021年4月连续接受Bif-FEVAR的患者。
- 仅纳入无合适肾下瘤颈且最低目标动脉与自体或人工主动脉分叉之间距离<70 mm的患者。
- 所有Bif-FEVAR定制器械由Cook Medical(Inc., Bloomington, Indiana)制造。
- 按血管外科学会标准分析人口学、解剖特征、技术成功、重大不良事件、30天死亡率及Kaplan-Meier生存。
- 共纳入10例患者,100%男性,中位年龄78岁。
主要发现
- 术前中位最大瘤径为68 mm[51-84]。
- 8例患者因腔内动脉瘤修复术后近端I型内漏接受治疗。
- 共计划36个开窗。
- 中位手术时间144 min[127-168],中位透视时间40.5 min[34-54],中位剂量面积乘积73 Gy cm2[61-89]。
- 技术成功率100%,无患者发生术后重大不良事件;中位随访时间8个月[6-13]。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To review the early experience of the use of a bifurcated-fenestrated endograft (Bif-FEVAR) to treat abdominal aortic aneurysms (AAA) in a high-volume aortic center. METHODS: A retrospective single-center analysis was conducted between March 2019 and April 2021 including consecutive patients that underwent Bif-FEVAR. Only patients without a proper infrarenal neck and a distance <70 mm between the lowest target artery and the native or prosthetic aortic bifurcation were considered. All Bif-FEVAR custom-made devices were manufactured by Cook Medical (Inc., Bloomington, Indiana). Demographics, anatomical features, technical success, major adverse events, 30-day mortality, and survival according to Kaplan-Meier were analyzed according to Society for Vascular Surgery standards. RESULTS: Overall, 10 patients (100% male with median age 78) were included. The median preoperative maximal aneurysm diameter was 68 mm [51-84]. Eight patients were treated for a proximal type I endoleak after endovascular aneurysm repair. A total of 36 fenestrations were planned. The median operative time was 144 min [127-168], with a median fluoro time of 40.5 min [34-54] and a median dose area product of 73 Gy cm2 [61-89]. Technical success rate was 100%. No patients experienced a major postoperative adverse event. Median follow-up time was 8 months [6-13]. CONCLUSION: Bif-FEVAR is technically feasible when there is a short distance below the lowest target artery and the aortic bifurcation, with favorable short-term results. CLINICAL IMPACT: This study assessed the use of an innovative one-piece bifurcated fenestrated stent-graft as a primary procedure or in the treatment of proximal endoleak after standard infrarenal EVAR. We demonstrated these custom-made devices can be used safely with favorable short-term results. One-piece bifurcated fenestrated stent-grafts extend the indications of FEVAR for patients with an unusually short distance between the lowest renal artery and the aorto-iliac bifurcation or the diverter flow of a preexisting bifurcated infrarenal stent-graft.
引用
- Mesnard T, Pruvot L, Oliver Patterson B, et al. Early Institutional Experience with One-Piece Bifurcated-Fenestrated Stentgraft in the Treatment of Abdominal Aortic Aneurysms. J Endovasc Ther. 2022. PMID: 36112831. doi:10.1177/15266028221119612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。